#1COPYRIGHT © ABCELLERA CORPORATE OVERVIEW JULY 2022 AbCellera#2CORPORATE OVERVIEW COPYRIGHT © ABCELLERA 2 DISCLAIMER This entation contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management's beliefs and assumptions and on information currently available to management. All statements contained in this presentation other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations. In some cases, you can identify forward-looking statements by the words "may," "will," "could," "would," "should," "expect," "intend," "plan," "anticipate," "believe,” “estimate," "predict," "project," "potential," "continue," "ongoing" or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this presentation represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.#3CORPORATE OVERVIEW COPYRIGHT © ABCELLERA 3 THE PROBLEM LIMITED TECHNOLOGIES & FRAGMENTED APPROACHES can't keep pace with antibody drug discovery. first 50 antibodies approved by FDA took 29 years 1986 .............. next 50 antibodies took 6 years 2015 * As at May 2021. Source: Nature Reviews: FDA approves 100th monoclonal antibody product 2021* OUR SOLUTION BRING BETTER ANTIBODIES TO PATIENTS, FASTER. We deliver lead candidates in less time and with a higher probability of success.#4CORPORATE OVERVIEW COPYRIGHT © ABCELLERA 4 WE HAD A BOLD VISION TO BUILD THE BEST CAPABILITIES IN THE WORLD FROM TARGET TO IND TARGETS SPECIFICATIONS Cellera WORKFORCE IND Engine TECHNOLOGY SOFTWARE + DATA SCIENCE INFRASTRUCTURE 2x faster solve the unsolvable highest quality unprecedented scale COMPOSITION OF MATTER Patentable DNA sequence of the drug IND Investigational New Drug Application DRUG SUBSTANCE GMP material for clinical testing#5CORPORATE OVERVIEW COPYRIGHT © ABCELLERA 5 WHERE WE ARE NOW WE PROVIDE PARTNERS WITH THE COMPETITIVE EDGE THEY NEED. 10+ ~$500M 500K+ 400+ YEARS OF EXPERTISE (founded in 2012) IN TECH DEVELOPMENT & ACQUISITIONS + SQ.FT. OF FACILITIES (total lab, office, & manufacturing spaces by 2024) EMPLOYEES#6CORPORATE OVERVIEW COPYRIGHT © ABCELLERA 6 WHERE WE'RE GOING FORWARD INTEGRATION TO ACCELERATE DRUG DEVELOPMENT. AbCellera Development 2012-2021: Antibody Discovery Tech Stack 4 SOURCE SEARCH DECODE ANALYZE ENGINEER TITL 2021-2024: Preclinical to IND Expansion into GMP / CMC Manufacturing eltera Partner Development Phase 1, 2, 3, Approval#7CORPORATE OVERVIEW COPYRIGHT © ABCELLERA 7 DISCLOSED PARTNERSHIPS PARTNERING WITH THE BEST DRUG DEVELOPERS OF ALL SIZES. We forge partnerships with large cap pharmaceutical companies, biotechnology companies of all sizes, and non-profit and government organizations through flexible deal structures: + royalties & milestones equity / equity-like (+) option to invest moderna gsk NOVARTIS igmences BILL & MELINDA GATES foundation EMPIRICO Autolus TACHYON Lilly EVEREST MEDICINES SANOFI KODIAK A DARPA Lyell GILEAD teva QEQR™ REMAKING MEDICINE Pfizer Ablynx A SANOFI COMPANY angios Invetx DENALI MERCK REGENERON#8FULL YEAR 2021 BUSINESS UPDATE COPYRIGHT © ABCELLERA 8 ILLUSTRATIVE REVENUE PROFILE FOR ONE SUCCESSFUL PARTNERED PROGRAM. AbCellera participation in programs is strongly weighted towards downstream success. Years since program start Stage of program development research fees $3 million 1y 2y 3y discovery & preclinical 4y phase 1 5y clinical milestones $9 million 6y 7y phase 2 8y 9y phase 3 10y approval & commercial milestones $85 million 11y 12y commercial sales 13y || 14y Key assumptions, hypothetical: $1.7 billion peak sales, no price inflation, no patient population growth, 5% royalty, 6 years to peak sales, 5 years at peak sales, US approval only 15y 16y 17y royalties in aggregate of $765 million 18y 19y 20y 21y#9FULL YEAR 2021 BUSINESS UPDATE COPYRIGHT © ABCELLERA 9 COVID-19 ANTIBODY PROGRAM. Similar revenue structure to typical program realized on a compressed timeline. Months since program start Stage of program development research fees <$5 million 3m discovery & preclinical approval & commercial milestones $14 million clinical milestones $8 million 6m 9m clinical development 12m 15m commercial sales royalties in aggregate of $526 million (to Dec 31, 2021), over 95% of total program revenue 18m 21m 24m#10FULL YEAR 2021 BUSINESS UPDATE COPYRIGHT © ABCELLERA 10 FOCUSSED ON KEY VALUE DRIVERS. 폈 Probability of Success Increase the probability of clinical and commercial success by identifying antibodies with superior biophysical properties. Speed Increase diversity at the start of discovery to maximize the likelihood that suitable leads are found on the first pass, avoiding unnecessary cyclical efforts. Integrating all steps of the process seamlessly results in faster workflows. % Portfolio Volume Large, diversified portfolio generates long-term value and superior returns without the volatility and risks normally associated with drug development. 1 Deal Structures Capture downstream value through royalties and milestones, equity / equity-like participation, and options to co-invest.#11CORPORATE OVERVIEW COPYRIGHT © ABCELLERA 11 LARGE DIVERSIFIED PORTFOLIO IN NEXT-GEN ANTIBODY THERAPIES. Portfolio of 131 programs with downstream participation is diversified across the following therapeutic areas: 39% human health, to be determined n = 51 58% oncology 50% human health, known n = 65 17% neurology 6% immunology 6% ophthalmology 5% infectious disease 3% dermatology 5% other 11% animal health n = 15#12CORPORATE OVERVIEW COPYRIGHT © ABCELLERA 12 OUR PARTNERS LOOK TO US TO UNLOCK NEW TARGETS & NEXT-GEN MODALITIES TARGETS MODALITIES 28% DIFFICULT targets M Y 0 multi-pass membrane targets IgGs, IgMs, IgAs CAR-T cell therapies radioisotope conjugates CNS-directed antibodies high homology targets Y bispecific antibodies anti-CD3 antibodies 72% STANDARD targets 83 & peptide-MHC targets Y single domains (VHH)#13CORPORATE OVERVIEW COPYRIGHT © ABCELLERA 13 CUSTOM-BUILT DATA SCIENCE ALLOWS SCALABLE INTEGRATION OF CUTTING-EDGE TECH WITH COMPUTATION & AI Addressing the compounding data complexities of antibody discovery requires the following: 1 Proprietary technologies that can generate massive multi-dimensional antibody datasets 2 Bo Proprietary data science software that integrates workflows and aggregates and stores data sets 3 Artificial intelligence and powerful computational tools to extract actionable information from this data#14CORPORATE OVERVIEW COPYRIGHT © ABCELLERA 14 TECH STACK MAKE EVERY STEP COUNT. Complex data integration driven by interlocking technologies optimizes each step with a compounding effect on the entire process. 1 SOURCE immune responses from multiple species 2 SEARCH millions of immune cells LEADS down-selection 3 DECODE hundreds of target-specific antibodies 4 ANALYZE hundreds to find dozens of candidates with desired properties 5 ENGINEER a few characterized & engineered leads DELIVER the best antibody drug candidates DATA ACCUMULATED#15CORPORATE OVERVIEW COPYRIGHT © ABCELLERA 15 SOURCE ENABLING TECHOLOGIES Optimized Immunization from any species, any target POWERED BY TRIANNI* Alloy Therapeutics TetraGenetics* ** SEARCH High-Throughput Single-Cell Screening with customizable secretion and functional assays AbCellera *** DECODE Automated Single-Cell Genomics & Repertoire Sequencing performed in parallel Lineage Biosciences' IgG Seq Platform* ANALYZE Customized Bioinformatics, High-Throughput Expression & Bioanalytics of high-confidence paired chains 18 CELIUM *** ENGINEER Protein Engineering & Multispecifics Development to create new antibody formats and optimize lead candidates OrthoMab Bispecific Platform* DATA ACCUMULATED * acquired ** in-licensed *** proprietary / patented#16CORPORATE OVERVIEW COPYRIGHT © ABCELLERA 16 LEADERSHIP TEAM TEAM IS EVERYTHING. Our founder-led team of 400+ employees includes engineers, data scientists, scientists, and business professionals. EXECUTIVES Andrew Booth, MBA Chief Financial Officer Tryn Stimart, JD Chief Legal & Compliance Officer Neil Aubuchon, MBA Chief Commercial Officer Carl Hansen, PhD Director, President & Chief Executive Officer Véronique Lecault, PhD Director & Chief Operating Officer Peter Thiel Director John Montalbano, CFA Director BOARD OF DIRECTORS Michael Hayden, MB, ChB, PhD, FRCP (C), FRSC, CM, OBC Lead Director Andrew Lo, PhD Director#17FINANCIALS CORPORATE OVERVIEW COPYRIGHT © ABCELLERA 17 Strong portfolio growth. Total # of Programs Under Contract Total # of Discovery Partners 36 158 Cumulative # of Program Starts 90 80 70 60 50 40 30 20 10 O 84 H 2014 2015 2016 2017 2018 2019 2020 2021 2022 Q1 WITHOUT downstream participation + WITH downstream participation 6 LO 5 4 3 2 1 O Cumulative # of Molecules in the Clinic 6 2014 2015 2016 2017 2018 2019 2020 2021 2022 Q1 Note: Showing year-end figures except for most recent quarter. Historical results are not necessarily indicative of future results.#18FINANCIALS CORPORATE OVERVIEW COPYRIGHT © ABCELLERA 18 6 molecules in the clinic, 2 authorized for emergency use. MOLECULE bamlanivimab (LY-CoV555) bebtelovimab (LY-CoV1404) NBL-012 NBL-015 NEW undisclosed IVX-01 STAGE Marketed, Emergency Use Authorization (EUA) Marketed, Emergency Use Authorization (EUA) Phase I IND approved IND approved Clinical field study PARTNER Lilly Lilly NovaRock BOTHERAPEUTICS NovaRock BOTHERAPEUTICS undisclosed Invetx™ THERAPEUTIC AREA ● ● ● ● ● ● infectious disease - COVID-19 infectious disease - COVID-19 dermatology gastrointestinal disease immunology oncology undisclosed animal health PROGRAM TYPE AbCellera Discovery Partnership Trianni License AbCellera Discovery Partnership As of March 31, 2022#19FINANCIALS CORPORATE OVERVIEW COPYRIGHT © ABCELLERA 19 Capital efficient growth as basis for ongoing investment. Cash Flow USD FROM OPERATIONS $4M FROM INVESTING¹ $3M ($5M) ($6M) FROM FINANCING $12M 2018 $OM 2019 $23M ($120M) ($85M) $684M $245M 2020 ($4M) 2021 $100M ($26M) ($9M) 2022YTD MAR 31 EMPLOYEES 55 CASH2, EQUIVALENTS & MARKETABLE SECURITIES USD $10M 107 2018 DEC 31 $8M 2019 1 Excluding investments in marketable securities 2 Including restricted cash 206 $564M 2020 386 $748M 2021 ~400 $811M 2022 MAR 31#20o COPYRIGHT © ABCELLERA TECH STACK 01 SOURCE OPTIMIZED IMMUNIZATION#21D 01 SOURCE. IMMUNIZATION OPTIMIZATION COPYRIGHT © ABCELLERA 21 ACCESS THE DATABASE OF NATURAL ANTIBODIES Natural immune systems contain a massively diverse database that encodes nature's answers for fighting disease. This database can be used to develop the drugs of the future, but it's been challenging to access the database. billions of unique antibodies inside each organism r To Y each is made by a single cell 00000 .... finding the best antibody = finding the cell that makes it Y 5 SOURCE SEARCH DECODE ANALYZE ENGINEER Powered by over 500 million years of evolution. Antibodies created by natural immune systems benefit from selection, quality assurance and optimization. ~92% of approved antibody drugs are derived from natural immune systems.#2201 SOURCE. IMMUNIZATION OPTIMIZATION COPYRIGHT © ABCELLERA 22 CONTROL IMMUNITY TO GENERATE BETTER DIVERSITY We generate and access a high-quality universe of antibodies for any target. DUMA proprietary immunization methods • tolerance breaking DNA immunization rapid immunization ● any source any tissue • wild type mice, rats • humanized rodents • camelids, cows, chickens, ● cats, dogs, rabbits directly from human donors KO animals TRIANNI Alloy Therapeutics human antibodies from rodents SOURCE SEARCH 5 DECODE ANALYZE ENGINEER "/=H We trigger immune responses from any species with the goal of generating the best antibodies, with the most diversity.#23O 01 SOURCE. IMMUNIZATION OPTIMIZATION COPYRIGHT © ABCELLERA 23 MORE HUMAN ANTIBODIES, FROM HUMANIZED MICE Source fully human antibodies from rodents to bypass the need to humanize sequences identified from non-humanized animals. With TRIANNI Flagship Mice: eliminate in vitro humanization and affinity maturation reduce drastically immuno- genicity concerns from non-human components lo generate robust responses equivalent to wild-type mice with fully functional immune systems 5 SOURCE SEARCH DECODE ANALYZE ENGINEER Diversity is our game. Integrated access to humanized mice, under competitive terms.#24o COPYRIGHT © ABCELLERA TECH STACK 02 SEARCH HIGH THROUGHPUT SINGLE-CELL SCREENING & FUNCTIONAL ASSAYS#2502 SEARCH. SINGLE-CELL SCREENING COPYRIGHT © ABCELLERA 25 DEEPLY SEARCH ANY ANTIBODY RESPONSE WITH MICROFLUIDIC SINGLE-CELL ASSAYS Multiple credit card-sized devices integrating hundreds of thousands of miniaturized chambers per device to screen millions of B cells: 出 0000 0000 0000 0000 <1 nL single-cell chamber 2 5 SOURCE SEARCH DECODE ANALYZE ENGINEER Each B cell is tested for the secretion of antibodies that bind to specific antigens. Positive binding is detected by high-throughput fluorescence microscopy and processed using machine vision.#2602 SEARCH. HIGH-THROUGHPUT SINGLE-CELL SCREENING COPYRIGHT © ABCELLERA 26 SEARCH FOR ANY ANTIBODY PROPERTY Secreted Antibodies Antibody- Secreting Cell AFFINITY YY Secreted Antibodies Antibody- Secreting Cell Labelled Antigens IgG-Coated Bead LIVE-CELL Oooo Secreted Antibodies Antibody- Secreting Cell Labelled Secondary Antibodies Antigen- Expressing Cells LIGAND-BINDING Secreted Antibodies Antibody- Secreting Cell Labelled Ligands Labelled Antigens IgG-Coated Bead Antigen-Coated Beads >> Secreted Antibodies SPECIFITY & CROSS-REACTIVITY Antibody- Secreting Cell COMBINATION 2 SOURCE SEARCH DECODE ANALYZE ENGINEER Labelled Secondary Antibodies Labelled Secondary Antibodies Antigen-Coated Beads Antigen- Expressing Cells 5#27o COPYRIGHT © ABCELLERA TECH STACK 03 DECODE AUTOMATED SINGLE-CELL GENOMICS & REPERTOIRE PROFILING#2803 AMPLIFY LEAD CANDIDATES WITH REPERTOIRE SEQUENCING DECODE. REPERTOIRE SEQUENCING COPYRIGHT © ABCELLERA 28 START FROM any source / species 1 SEARCH single cells 2 DECODE single cells in parallel 2 SEQUENCE immune repertoire O 00000 oooo 0000000 OOOOO 3 ANALYZE sequences mm EXPRESS, CHARACTERIZE, VALIDATE high confidence paired chains 0000 0000 K ↑. iterative ●000 5 MAP, ANNOTATE, PAIR lead seeds CELIUM مممله ঋ SOURCE SEARCH DECODE ANALYZE ENGINEER 5 SELECT new antibody pairs#2903 DECODE. REPERTOIRE SEQUENCING COPYRIGHT © ABCELLERA 29 SINGLE-CELL LEAD LINEAGE TREE S G S S R G Germline S Single-Cell SR Single-Cell / Repertoire R Repertoire Inferred ADDITIONAL LEADS LINEAGE TREE R R SR G R R R R R R R R R R R (R AMPLIFY OPTIONS FROM A SINGLE-CELL LEAD THROUGH R R R O SOURCE SEARCH DECODE ANALYZE ENGINEER REPERTOIRE SEQUENCE MAPPING R POWERED BY 18 5 CELIUM#30o COPYRIGHT © ABCELLERA TECH STACK 04 ANALYZE CUSTOMIZED BIOINFORMATICS, HIGH-THROUGHPUT EXPRESSION & BIOANALYTICS#3104 ANALYZE. BIOINFORMATICS & VISUALIZATION COPYRIGHT © ABCELLERA 31 SEE THE BIG PICTURE WITH MEANINGFUL DATA. Grasp the complexity of large single cell antibody datasets. Celium™, our proprietary software brings data to life. Designed to visually explore data, interrogate every parameter, and rapidly inform downstream selection and validation. Compare data based on: ● clonal relatedness binding specificity biophysical characteristics Identity to germline ● ● ● V-gene usage functional properties sequence similarities Animal/patient source SOURCE SEARCH DECODE ANALYZE ENGINEER 5 heavy chain ¡ antibody pair light chain POWERED BY CELIUM#3204 ANALYZE. BIOINFORMATICS & VISUALIZATION COPYRIGHT © ABCELLERA 32 SELECT THE BEST, OF THE BEST. Use developability information to help select your best leads. Validate hundreds of antibodies with high-throughput expression and characterization capabilities. POWERED BY 8 CELIUM HIGH-THROUGHPUT EXPRESSION YOY XX Y PURITY BINDING VALIDATION STABILITY FUNCTIONAL VALIDATION 000 OLIGOMERIZATION S IL. SOURCE SEARCH DECODE ANALYZE ENGINEER EPITOPE BINNING AFFINITY 5 f#33COPYRIGHT © ABCELLERA TECH STACK 05 ENGINEER PROTEIN ENGINEERING & MULTISPECIFICS DEVELOPMENT#3405 ENGINEER. EXPRESSION & BIOANALYTICS COPYRIGHT © ABCELLERA 34 COMBINE ANY TWO ANTIBODIES TO CREATE NATIVE BISPECIFICS. Example mutations at a heavy-light chain (Fab) interface: V₁ ........ VH mutation A CH STANDARD PARENTAL IgG's HI mutation B BISPECIFIC IgG mutation C 5 SOURCE SEARCH DECODE ANALYZE ENGINEER 3 protein-protein interfaces with 1 to 4 mutations per domain to ensure correct and stable pairing of multiple heavy (V₁ CH) and light (V₁ C₁) chains#3505 ENGINEER. EXPRESSION & BIOANALYTICS COPYRIGHT © ABCELLERA 35 IMPROVE DEVELOPMENT OF BISPECIFICS WITH A CLINICALLY-VALIDATED PLATFORM. Faster development with native IgG-like format. Diverse panels. ● Optimized discovery yields large and diverse panels Full IgG format with other additional engineering option Predictable development from native antibody format Stable + manufacturable. ● Standardized mAb protocols Less optimization Integrates into one stable cell line production SOURCE SEARCH DECODE ANALYZE ENGINEER Proven platform. Immunogenicity analysis using EpiVax platform included 5 Technology validated in clinic by large biopharma#3605 ENGINEER. EXPRESSION & BIOANALYTICS COPYRIGHT © ABCELLERA 36 ENGINEER FIT-FOR-PURPOSE LEAD ANTIBODY CANDIDATES. Our protein engineering tool-kit supports next-generation antibody therapeutics, such as VHH constructs, humanization, deimmunization, optimization, reformatting, and most recently, bispecific antibodies that enable the following therapeutic modalities: CELLULAR CO-LOCALIZATION RECEPTOR HETERODIMERIZATION PROTEIN SCAFFOLDING SOURCE SEARCH DECODE ANALYZE ENGINEER 5 PK / PD MANIPULATION#37COPYRIGHT © ABCELLERA 37 ABCELLERA INVESTOR RELATIONS [email protected]